Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

BACKGROUND: Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for this effect. We investigated the safety and efficacy of the combination of the IGF-1R antibody cixutum...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Schwartz, Gary K, Tap, William D, Qin, Li-Xuan, Livingston, Michael B, Undevia, Samir D, Chmielowski, Bartosz, Agulnik, Mark, Schuetze, Scott M, Reed, Damon R, Okuno, Scott H, Ludwig, Joseph A, Keedy, Vicki, Rietschel, Petra, Kraft, Andrew S, Adkins, Douglas, Van Tine, Brian A, Brockstein, Bruce, Yim, Vincent, Bitas, Christiana, Abdullah, Abdul, Antonescu, Cristina R, Condy, Mercedes, Dickson, Mark A, Vasudeva, Shyamprasad Deraje, Ho, Alan L, Doyle, L Austin, Chen, Helen X, Maki, Robert G
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3766955/
https://ncbi.nlm.nih.gov/pubmed/23477833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70049-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares